

## Index to Volume 42

The Index to Volume 42 is composed of three parts; an Author Index, a Subject Index and an Advertisers' Index.

### Author Index

All contributing authors are listed alphabetically with the surname first and initials following. If there is more than one author, the submission title is documented under the author name which appeared first when published in the *Journal*. All other authors are listed referring to that name.

### Subject Index

The Subject Index is comprised mainly of terms found in the "Key Words" section of abstracts, and also from principal words selected from titles listed in the Table of Contents of each issue. Separate sections in the Subject Index identify titles not found in the Table of Contents under the headings of "Book Reviews" and "Letters to the Editor". Also itemized separately are

"Editorials" and the "President's Report". *Journal* and Society business can be found under "Canadian Journal of Hospital Pharmacy" and "Canadian Society of Hospital Pharmacists".

### Advertisers' Index

The Advertisers' Index lists the company name followed by sub-headings of the products advertised. The issue number (as identified below) precedes the page number where the advertisement appears.

Number	Issue	Pages	
		Numerical	Arabic
1	February	1- 52	i-xvi
2	April	53- 92	i-xvi
3	June	93-134	i-xxii
4	August	135-170	i-xxii
5	October	171-220	i-xxvi
6	December	221-270	i-xxii

## Author Index

- |                                                                                                               |     |                                                                                                                                 |     |
|---------------------------------------------------------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------|-----|
| Anderson PO, Knoblen JE.<br>Handbook of clinical drug data (Letter) .....                                     | 95  | Chan J.<br>Methotrexate for the treatment of<br>corticosteroid-dependent asthma .....                                           | 39  |
| Andrews JD, Shokar P.<br>Inappropriate intravenous administration<br>of ranitidine and associated costs ..... | 185 | Collins DS.<br>see McNaught AK. ....                                                                                            | 161 |
| Ariano RE, Lepinski P.<br>Tyrosine and tryptophan in the management<br>of cocaine withdrawal .....            | 207 | see Reilly K. ....                                                                                                              | 205 |
| Barnett JB.<br>see Grant SM. ....                                                                             | 147 | Coons C, Sone M.<br>Portable narcotic infusion devices in Canada .....                                                          | 235 |
| Bayliff CD.<br>see McNaught AK .....                                                                          | 161 | Cote D, Oruck J, Thickson N.<br>A review of the Manitoba home IV<br>antibiotic program .....                                    | 137 |
| Bethea C.<br>see Das Gupta V. ....                                                                            | 109 | Cseke W.<br>see Moleschi M. ....                                                                                                | 157 |
| Blain L, O'Brodovich M.<br>The effect of an education program on<br>cefazolin prescribing .....               | 69  | Das Gupta V, Parasrampur J, Bethea C, Wright W.<br>Stability of clindamycin phosphate in dextrose and<br>saline solutions ..... | 109 |
| Blanchard C, Donnelly R.<br>Clomipramine suspension formulations .....                                        | 248 | Donnelly R.<br>see Blanchard C. ....                                                                                            | 248 |
| Bornstein C.<br>Drugs and aging (Book Review) .....                                                           | 43  | Drum D.<br>see Rovers JP. ....                                                                                                  | 143 |
| Brownscombe L.<br>see Hart TL. ....                                                                           | Dec | Dupuis LL.<br>see Johnson N. ....                                                                                               | 57  |
| Cameron A.<br>Keeping track of P&T activities (Letter) .....                                                  | 136 | Edmonds MW.<br>see Hart TL. ....                                                                                                | 243 |

## Index to Volume 42

The Index to Volume 42 is composed of three parts; an Author Index, a Subject Index and an Advertisers' Index.

### Author Index

All contributing authors are listed alphabetically with the surname first and initials following. If there is more than one author, the submission title is documented under the author name which appeared first when published in the *Journal*. All other authors are listed referring to that name.

### Subject Index

The Subject Index is comprised mainly of terms found in the "Key Words" section of abstracts, and also from principal words selected from titles listed in the Table of Contents of each issue. Separate sections in the Subject Index identify titles not found in the Table of Contents under the headings of "Book Reviews" and "Letters to the Editor". Also itemized separately are

"Editorials" and the "President's Report". *Journal* and Society business can be found under "Canadian Journal of Hospital Pharmacy" and "Canadian Society of Hospital Pharmacists".

### Advertisers' Index

The Advertisers' Index lists the company name followed by sub-headings of the products advertised. The issue number (as identified below) precedes the page number where the advertisement appears.

Number	Issue	Pages	
		Numerical	Arabic
1	February	1- 52	i-xvi
2	April	53- 92	i-xvi
3	June	93-134	i-xxii
4	August	135-170	i-xxii
5	October	171-220	i-xxvi
6	December	221-270	i-xxii

## Author Index

- |                                                                                                               |     |                                                                                                                                 |     |
|---------------------------------------------------------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------|-----|
| Anderson PO, Knoblen JE.<br>Handbook of clinical drug data (Letter) .....                                     | 95  | Chan J.<br>Methotrexate for the treatment of<br>corticosteroid-dependent asthma .....                                           | 39  |
| Andrews JD, Shokar P.<br>Inappropriate intravenous administration<br>of ranitidine and associated costs ..... | 185 | Collins DS.<br>see McNaught AK. ....                                                                                            | 161 |
| Ariano RE, Lepinski P.<br>Tyrosine and tryptophan in the management<br>of cocaine withdrawal .....            | 207 | see Reilly K. ....                                                                                                              | 205 |
| Barnett JB.<br>see Grant SM. ....                                                                             | 147 | Coons C, Sone M.<br>Portable narcotic infusion devices in Canada .....                                                          | 235 |
| Bayliff CD.<br>see McNaught AK .....                                                                          | 161 | Cote D, Oruck J, Thickson N.<br>A review of the Manitoba home IV<br>antibiotic program .....                                    | 137 |
| Bethea C.<br>see Das Gupta V. ....                                                                            | 109 | Cseke W.<br>see Moleschi M. ....                                                                                                | 157 |
| Blain L, O'Brodovich M.<br>The effect of an education program on<br>cefazolin prescribing .....               | 69  | Das Gupta V, Parasrampur J, Bethea C, Wright W.<br>Stability of clindamycin phosphate in dextrose and<br>saline solutions ..... | 109 |
| Blanchard C, Donnelly R.<br>Clomipramine suspension formulations .....                                        | 248 | Donnelly R.<br>see Blanchard C. ....                                                                                            | 248 |
| Bornstein C.<br>Drugs and aging (Book Review) .....                                                           | 43  | Drum D.<br>see Rovers JP. ....                                                                                                  | 143 |
| Brownscombe L.<br>see Hart TL. ....                                                                           | Dec | Dupuis LL.<br>see Johnson N. ....                                                                                               | 57  |
| Cameron A.<br>Keeping track of P&T activities (Letter) .....                                                  | 136 | Edmonds MW.<br>see Hart TL. ....                                                                                                | 243 |

Einarson TR. see Ilersich AL. ....	89	Lau DWC. see Walker SE. ....	97
see Taras-Zasowski KM. ....	105	see Walker SE. ....	195
Einarson TR, Mann JL. Survey of pharmacotherapy monitoring in Canadian acute care hospitals .....	229	Lepinski P. see Ariano RE. ....	207
Einarson TR, Segal HJ, Mann JL. Serum drug level utilization: a literature analysis .....	63	Long S. Strategic management of hospitals and health care facilities (Book Review) .....	121
Fallon K. see Rappaport P. ....	73	Lynd LD. see McCormack JP. ....	3
Fowler R. Disclosure of non medicinal ingredients (Letter) .....	55	Macnab KA. Cross allergenicity of penicillins and cephalosporins .....	81
Friesen CE. The role of the hospital pharmacist in community-based health care .....	113	Madorin PL. see Walker SE. ....	97
Gaucher M. Computers in hospital pharmacy practice (Attention Program) .....	45	Madsen M, Taylor GD. Intravenous vancomycin usage in a tertiary care hospital .....	153
Gervais AA. see Johnson NG. ....	77	Mallet L, Spruill WJ, Morton MR. Review of phenytoin usage in long term care facilities .....	17
Godbout L. see Torsher L. ....	117	Mann JL. see Einarson TR. ....	63
Grant SM, Barnett JB. A review of megestrol versus cyproterone in prostate cancer .....	147	see Einarson TR. ....	229
Hall KW. see Manness LJ. ....	31	Manness LJ, Morton B, Tarasoff C, Hall KW. The development of a computerized hospital pharmacy workload measurement reporting system .....	31
Hart TL, Johnson LJ, Edmonds MW, Brownscombe L. Hyponatremia secondary to thiazide- trimethoprim interaction .....	243	Marshall L. see Wasan S. ....	239
Ho K, Spino M. Theophylline in asthma: once versus twice-daily dosing .....	173	McCormack, JP, Lynd LD, Pfeifer NM. Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service .....	3
Iazzetta J. see Walker SE. ....	97	McGregor KE. Accidental drug administration (Letter) .....	55
see Walker SE. ....	195	Emergency and investigational drug procedures (Letter) .....	95
Ilersich AL, Einarson TR. Adverse drug reactions: the scale and nature of the problem and the way forward (Book Review) .....	89	McLean W, Lalonde R, Roy M. The history of a comprehensive pharmacokinetic service .....	223
James G. see Rappaport P. ....	73	McLurg D, Repchinsky C. Iodine for fibrocystic breast disease? .....	87
Jamieson W. see Reilly K. ....	205	McNaught AK, Bayliff CD, Paterson NAM, Collins DS. Benzodiazepine-induced respiratory depression .....	161
Johnson NG, Dupuis LL. A quality assurance audit of a drug information service .....	57	Meineilly G. see Rovers JP. ....	143
Johnson NG, Gervais AA, Wilson KB. A missing dose audit of a centralized unit dose drug distribution system .....	77	Moleschi M, Cseke W, Roy L. Pharmacy service to distant small hospitals .....	157
Johnson LJ. see Hart TL. ....	243	Moran-Murray E. Protocols for evaluating ambulatory care: volume 2 - drug usage evaluation (Book Review) .....	90
Jovaisas B, Yen M. Cefoxitin utilization review .....	191	Morton B. see Manness LJ. ....	31
Jung B, Trotter LR. A review of cimetidine dosing in the elderly .....	201	Morton MR. see Mallet L. ....	17
Karakolis S. Nitrate tolerance .....	119	Murdoch J. The use of antibiotics: a comprehensive review with clinical emphasis — fourth edition (Book Review) .....	168
Knoben JE. see Anderson PO. ....	95	Feverfew for migraine prophylaxis .....	209
Krstenansky PM. Pentamidine aerosol in pneumocystis carinii pneumonia (PCP) .....	164	Murdoch L. Newletters with impact (Editorial) .....	1
Laher J. Methotrexate interaction with nonsteroidal anti-inflammatory drugs .....	37	Nairn JG. Pharmaceutical dosage forms: disperse systems — volume 1 (Book Review) .....	89
Lalonde R. see McLean W. ....	223	Nazeravich D. CSHP statement on institutional pharmacy research (CSHP Research Committee) .....	215

O'Brodovich M.		Steeves R.	
The recruitment challenge (Editorial) .....	53	The future for membership definitions and the	
see Blain L. ....	69	organization of CSHP (President's Report) .....	46
The annual meeting — Can we boost		CSHP and the two official languages (President's Report) ....	91
attendance? (Editorial) .....	221	CSHP education programs (President's Report) .....	122
Oruck J.		The strategic planning process: a president's view	
see Cote D. ....	137	towards his future in CSHP (President's Report) .....	169
Otchenash W.		Sungaila I.	
Unit dose in a 50-bed hospital .....	79	Pharmacokinetics and pharmacodynamics — volume 2.	
		Current problems — potential solutions (Book Review) ....	211
Parasrampur J.		Taylor S.	
see Das Gupta V. ....	109	Psychotropic drug handbook — fifth edition	
Paterson NAM.		(Book Review) .....	43
see McNaught AK. ....	161	Taras-Zasowski KM, Eiarson TR.	
Paton T.		Review of Canadian pharmacist involvement in	
see Yamashita S. ....	10	adverse drug reaction reporting .....	105
Pfeifer NM.		Tarasoff C.	
see McCormack JP. ....	3	see Manness LJ. ....	31
Phillips L.		Taylor GD.	
Tetracycline overdoses and tooth-staining in children .....	247	see Madsen M. ....	153
Plosker GL.		Thickson N.	
Amikacin and gentamicin-resistant, tobramycin-sensitive		see Cote D. ....	137
pseudomonas aeruginosa .....	86	Thompson DF.	
		Treatment of multiple sclerosis with interferon .....	40
Rappaport P.		Torsher L, Godbout L.	
The health care supervisor's handbook		The treatment of systemic lupus	
(Book Review) .....	167	erythematosus (SLE) in pregnancy .....	117
Rappaport P, Fallon K, James G.		Tremblay SJ.	
Daily packaging of non standard oral unit		The bliss of year end (Editorial) .....	93
doses for pediatrics .....	73	Pharmacy misses out on recognition (Editorial) .....	135
Reilly K, Collins D, Jamieson W.		The state of hospital pharmacy practice (Editorial) .....	171
Cafergot®-induced vasospasm .....	205	Trottier LR.	
Rekhi GS.		see Jung B. ....	201
see Rovers JP. ....	143	Van der Vliet W.	
Repchinsky C.		Prostate cancer — treatment review .....	21
see McLurg D. ....	87	Walker SE, Iazzetta J, Lau DWC.	
Richard A, Zhanel G.		Stability of sulfite free high potency morphine sulfate	
Treatment of vaginal pinworms .....	208	solutions in portable infusion pump cassettes .....	195
Rosenbloom D.		Walker SE, Iazzetta J, Lau DWC, Madorin PL.	
Pharmacoepidemiology: an introduction (Book Review) .....	211	Famotidine stability in total parenteral nutrient	
Rovers JP, Meneilly G, Souney PF, Rekhi GS, Drum D.		solutions .....	97
The use of stability-indicating assays to determine the		Wasan S, Marshall L.	
<i>in vitro</i> compatibility and stability of		An adverse drug reaction reporting program .....	239
metronidazole/gentamicin admixtures .....	143	Wilson KB.	
Roy L.		see Johnson NG. ....	77
see Moleschi M. ....	157	Worthington I.	
Roy M.		Bronchoconstriction due to benzalkonium chloride	
see McLean W. ....	223	in nebulizer solutions .....	166
Ruston L.		The pharmacist's answer book (Book Review) .....	251
Cutaneous side effects of drugs (Book Review) .....	167	Wright W.	
Salsman B.		see Das Gupta V. ....	109
Membership — your Society needs you!		Wurtz DW.	
(President's Report) .....	213	Fellow non PEBC pharmacists (Letter) .....	55
CSHP office staff .....	216	Yamamoto A.	
CSHP office relocation (President's Report) .....	253	IV guanethidine for nerve blocks .....	85
Segal HJ.		Antibiotic prophylaxis for dental patients	
see Einarson TR. ....	63	with joint prosthesis .....	248
Shokar P.		Yamashita S, Paton T.	
see Andrews JD. ....	185	The effects of warfarin and heparin on	
Smith J.		anticoagulation tests .....	10
Pediatric drug dosage handbook (Book Review) .....	250	Yen M.	
Sone M.		see Jovaisas B. ....	191
see Coons C. ....	235	Young B.	
Souney PF.		Handbook of clinical drug data — sixth edition	
see Rovers JP. ....	143	(Book Review) .....	42
Spino M.		Zhanal G.	
see Ho K. ....	173	see Richard A. ....	208
Spruill WJ.			
see Mallet L. ....	17		

# Subject Index

- Adverse Drug Reaction Reporting  
involvement in ..... 105  
program ..... 239
- Allergy  
penicillins and cephalosporins ..... 81
- Amikacin  
and pseudomonas aeruginosa ..... 86
- Aminoglutethimide  
in prostate cancer ..... 21
- Aminoglycosides  
and pseudomonas aeruginosa ..... 86
- Annual Meeting  
Editorial ..... 221
- Anti-Inflammatory Agents  
non steroidal ..... 37
- Antibiotic  
home IV program ..... 137  
prophylaxis for dental patients ..... 248
- Anticoagulation Tests  
effects of warfarin and heparin on ..... 10
- Asthma  
treatment with methotrexate ..... 39  
and theophylline dosing ..... 173
- Attention Program  
Computers in hospital pharmacy practice ..... 45
- Benzalkonium Chloride  
and bronchoconstriction ..... 166
- Benzodiazepines  
and respiratory depression ..... 161
- Book Reviews  
Adverse drug reactions: the scale and nature  
of the problem and the way forward ..... 89  
Cutaneous side effects of drugs ..... 167  
Drugs and aging ..... 43  
Handbook of clinical drug data — sixth edition ..... 42  
Pediatric drug dosage handbook — sixth edition ..... 250  
Pharmaceutical dosage systems:  
disperse systems — volume 1 ..... 89  
Pharmacoepidemiology: and introduction ..... 211  
Pharmacokinetics and pharmacodynamics:  
volume 2: Current problems —  
potential solutions ..... 211  
Protocols for evaluating ambulatory  
care — volume 2 ..... 90  
Psychotropic drug handbook — fifth edition ..... 43  
Strategic management of hospitals  
and health care facilities ..... 121  
The health care supervisor's handbook ..... 167  
The pharmacist's answer book ..... 251  
The use of antibiotics. A comprehensive review  
with clinical emphasis — fourth edition ..... 168
- Bronchoconstriction  
Due to benzalkonium chloride in  
nebulizer solutions ..... 166
- Cafergot  
induced vasospasm ..... 205
- Canadian Journal of Hospital Pharmacy  
CJHP Index to Advertisers ..... 1:xvi, 2:xiii,  
133, 4:xix  
5:xix, 6:xvi  
CJHP Objectives ..... i (all issues)  
CJHP Table of Contents ..... iii (all issues)  
Guidance for Authors ..... 49, 62, 104,  
142, 184, 242  
Recommendations aux Auteurs ..... 50, 72, 134, 270  
Tribute to Journal volunteers ..... 261  
Tribute to Journal reviewers ..... 261  
Tribute to Journal translators ..... 261
- Canadian Society of Hospital Pharmacists  
1989/90 Officers ..... 252  
Annual General Meeting ..... 255  
Annual Report Notice ..... 251  
Appointments ..... 44, 80, 95, 160,  
5:xvii, 269  
Announcements ..... 136, 210  
Awards  
23rd annual 1988/89 award presentations ..... 127  
1988 meritorious service award recipient ..... 48  
1989 distinguished service award recipient ..... 128  
Call for 1989/90 submissions ..... 132  
Deadline for 1989/90 submissions ..... 160  
Tribute to 1988/89 appraisers ..... 127  
Call for Posters and Contributed Oral  
Presentations ..... 212  
Calendar of Events ..... 92  
Call for Resolutions ..... 78, 121  
Canadian Drug Information  
Centres — updates ..... 1:xii, 94  
Grants to CSHP ..... 132  
In Memoriam ..... 51  
Mission Statement ..... 260  
New Cytotoxic Symbol ..... 1:xvi, 2:xiii, 3:xiv  
Nominations for Meritorious Service Award ..... 2:x  
Notice of Impending Bylaw Changes ..... 78, 121  
Notice of Nominations for 1989/90 Officers ..... 2:xi  
Office Staff ..... 216  
Office Relocation ..... 5:xxi, 253  
Professional Practice Conference ..... 124  
Publications Available from CSHP ..... 84  
Resolutions to 42nd Annual Meeting ..... 258  
Statement on Institutional Pharmacy Research ..... 215
- Cefazolin  
prescribing ..... 69
- Cefoxitin  
utilization review ..... 191
- Cephalosporins  
and penicillins ..... 81
- Cimetidine  
dosing in the elderly ..... 201
- Clindamycin  
stability of ..... 109
- Clinical Pharmacy  
adverse drug reaction reporting ..... 105
- Clomipramine  
suspension formulations ..... 248



Cocaine Withdrawal management with tyrosine and tryptophan .....	207	Hormone Treatment in prostate cancer .....	147
Community-Based Health Care pharmacist's role in .....	113	Hyponatremia and thiazide-trimethoprim interaction .....	243
Computers workload measurement reporting system .....	31	Infusion Devices portable narcotic .....	235
Attention Program .....	45	Infusion Pump Cassettes morphine sulfate solutions in .....	195
and non standard oral unit dose packaging .....	73	Interferon in multiple sclerosis .....	40
Cost Containment of vancomycin .....	3	Iodine for fibrocystic breast disease .....	87
Cost Control in prostate cancer .....	147	Ketoconazole in prostate cancer .....	21
Cyproterone treatment review in prostate cancer .....	21	LHRH Agonists in prostate cancer .....	21
versus megestrol in prostate cancer .....	147	Languages President's Report .....	91
Diethylstilboestrol in prostate cancer .....	21	Letters to the Editor Accidental drug administration .....	55
Drug Information Service quality assurance audit of .....	57	Disclosure of non medicinal ingredients .....	55
Drug Level Utilization serum .....	63	Fellow non PEBC pharmacists .....	55
Drug Stability famotidine and total parenteral nutrient solutions .....	97	Emergency and investigational drug procedures .....	95
of clindamycin phosphate .....	109	Handbook of clinical drug data .....	95
of metronidazole/gentamicin admixtures .....	143	Keeping track of P&T activities .....	136
of morphine sulfate solutions .....	195	Long-Term Care Facilities and phenytoin usage .....	17
Drug Tolerance and nitrates .....	119	Megestrol treatment review in prostate cancer .....	21
Drug Utilization Review of phenytoin usage .....	17	versus cyproterone in prostate cancer .....	147
in cefazolin prescribing .....	69	Membership President's Report .....	46
of vancomycin usage .....	153	President's Report .....	213
of ranitidine .....	185	Methotrexate and non steroidal anti-inflammatory drugs .....	37
of cefoxitin .....	191	and asthma .....	39
of cimetidine dosing .....	195	Metronidazole and gentamicin admixtures .....	143
Editorials Newsletters with impact .....	1	Migraine Prophylaxis feverfew for .....	209
The recruitment challenge .....	53	Missing Doses in a unit dose drug distribution system .....	77
The bliss of year end .....	93	Morphine stability of .....	195
Pharmacy misses out on recognition .....	135	Multiple Sclerosis treatment with interferon .....	40
The state of hospital pharmacy practice .....	171	Narcotic portable infusion devices .....	235
The annual meeting — Can we boost attendance? .....	221	Nebulizer Solutions and benzalkonium chloride .....	166
Education and cefazolin prescribing .....	69	Nerve Blocks IV guanethidine for .....	85
President's Report .....	122	Newsletters Editorial .....	1
Elderly and phenytoin usage .....	17	Nitrates tolerance of .....	119
and cimetidine dosing .....	201	Non Steroidal Anti-Inflammatory Drugs methotrexate interaction with .....	37
Famotidine stability .....	97	Office Relocation President's Report .....	253
Feverfew for migraine prophylaxis .....	209	Outpatient Programs home IV antibiotics .....	137
Fibrocystic Breast Disease and iodine .....	87	Packaging unit dose .....	73
Flutamide in prostate cancer .....	21	Pediatrics packaging of unit doses for .....	73
Formulations clomipramine suspension .....	248	Penicillins and cephalosporins .....	81
Gentamicin and pseudomonas aeruginosa .....	86		
and metronidazole admixtures .....	143		
Guanethidine for nerve blocks .....	85		
Heparin and warfarin .....	10		
Home IV Antibiotic Program in Manitoba .....	137		

Pentamidine in pneumocystis carinii pneumonia (PCP) .....	164	Respiratory Depression and benzodiazepines .....	161
Peripheral Neuralgia IV guanethidine for .....	85	Side Effects adverse drug reaction reporting .....	105
Pharmacist's Role in community-based health care .....	113	Small Hospitals unit dose in .....	79
Pharmacokinetics drug monitoring service .....	3	pharmacy service to .....	157
phenytoin usage .....	17	Strategic Planning President's Report .....	169
and pharmacy services .....	223	Systemic Lupus Erythematosus (SLE) in pregnancy .....	117
Pharmacotherapy and adverse drug reaction reporting .....	105	Theophylline in asthma .....	173
monitoring in acute care hospitals .....	229	Tetracycline and tooth-staining in children .....	247
Pharmacy Misses Out Editorial .....	135	Thiazide and hyponatremia .....	243
Pharmacy Practice Editorial .....	171	Tobramycin and pseudomonas aeruginosa .....	86
Pharmacy Services to distant small hospitals .....	157	Tooth-Staining and tetracycline overdoses .....	247
and pharmacokinetics .....	223	Total Parenteral Nutrient Solutions famotidine stability in .....	97
Phenytoin usage in long term care facilities .....	17	Trimethoprim and hyponatremia .....	243
Pinworms treatment of vaginal .....	208	Tryptophan and cocaine withdrawal .....	207
Pneumocystis Carinii Pneumonia (PCP) pentamidine aerosol in .....	164	Tyrosine and cocaine withdrawal .....	207
Pregnancy and systemic lupus erythematosus (SLE) .....	117	Unit Dose for pediatrics .....	73
President's Reports The future for membership definitions and the organization of CSHP .....	46	and a missing dose audit .....	77
CSHP and the two official languages .....	91	in a 50-bed hospital .....	79
CSHP education programs .....	122	Utilization serum drug level .....	63
The strategic planning process: a president's view towards his future in CSHP .....	169	Vancomycin cost containment .....	3
Membership — your Society needs you .....	213	drug utilization review .....	153
CSHP Office Relocation .....	253	Vasospasm cafergot-induced .....	205
Prostate Cancer treatment review .....	21	Warfarin and heparin .....	10
megestrol versus cyproterone .....	147	Workload Measurement development of computerized reporting system .....	31
Pseudomonas Aeruginosa and aminoglycosides .....	86	Year End Editorial .....	93
Quality Assurance and drug information .....	57		
Ranitidine inappropriate intravenous administration of .....	185		
Recruitment Editorial .....	53		